| Chun, 2020 |
30H, 12U, 26B, 17 T |
29H, 12U, 17B, 27 T |
4 (Pain 2,bleed 2, f0, perf0) |
9 (pain 2, bleed 3, fever3, perf1) |
82/85 (malig); 3/85 (benign) |
83/85 (malig); 2/85 (benign) |
6 m |
PDAC 80, MCN w/invasive CA 1, mets in LN 1 |
PDAC 78, IPMN w/invasive CA 3, NET 2 |
| Zhou, 2020 |
186H, 22U, 85B, 79 T |
NR |
NR |
57/385 (malig); 135/385 (susp); 72/89 (benign) |
157/385 (malig); 105/385 (susp); 78/89 (benign) |
6 m |
AIP 1, Pseudocyst 6, PDAC 3 |
AIP 1, Pseudocyst 6, PDAC4, AC 1 |
| Hashimoto, 2017 |
64H, 34B, 14 T |
76H, 54B, 23 T |
NR |
NR |
92/112 (malig); 20/112 (benign) |
136/153 (malig); 17/153 (benign) |
NR |
PDAC 85, NET 1, Metastatic 3, Carcinoma 1, SPN 1, Lymphoma 1, AIP 6, Inflamm 11, benign tumor 3 |
PDAC 122, NET 10,Metastatic 2, Carcinoma 1, SPN 1, Inflamm 6, AIP 7, Benign 4 |
| De Luna, 2004 |
– |
– |
– |
– |
34/67 (malig); 7/64 (atypical/susp) |
22/51 (malig); 12/51 (atypical/susp) |
13 m (8–26 m) |
44 PDAC, 2 MCN, 1 islet cell tumor, 19 inflammatory, 1 microcystic adenoma |
| Lee, 2016 |
5H, 16B, 15 T |
– |
– |
25/36 (malig); 9/36 (susp); 0/36 (benign) |
15/36 (malig); 11/36 (susp); 4/36 (benign) |
12 m |
PDAC 48 |
| 5H, 5B, 2 T |
– |
– |
9/12 (malig); 1/12 (susp); 2/12 (benign) |
7/12 (malig); 2/12 (susp); 2/12 (benign) |
| Qin, 2014 |
50H, 22B/T |
– |
– |
42/60 (malig); 12/12 (benign) |
44/60 (malig); 12/12 (benign) |
12 m (3–16) |
AdenoCA 41, NET 1,Panc TB 10, CP 2 |
AdenoCA 42, NET 2, Panc TB 10, CP 2 |
| Lee, 2011 |
13H, 10U, 9N, 22B, 4 T |
None |
30/58 (malig); 11/58 (susp); 9/58 (benign) |
11/58 (malig); 22/58 (susp); 5/58 (benign) |
NR |
Panc CA 36, Malig IPMN 3, Cholangio 2, Lymphoma 1, AoV CA 1, Mets 1, SCA 3, Simple cyst 3, Desmoid/GIST/Inflamm/NET/Adipose T/Granuloma 1 each |
| Van Riet, 2020 |
34H, 6U, 4N, 14C, 13 T |
None |
47/71 (malignant) |
30/42 (malignant) |
12 m |
Benign 4, Malig 64, Atypical (NET, Pancreatitis) 3 |
| Yeon, 2018 |
18H, 6U, 7B, 12 T |
– |
– |
24/48 (malig); 20/48 (benign) (48 specimen) |
17/48 (malig); 20/48 (benign) (48 specimen) |
6 m |
NR |
